Protagonist Therapeutics 11/7/2024 Earnings Report $36.99 -1.00 (-2.63%) As of 02/11/2025 04:00 PM Eastern Earnings HistoryForecast Protagonist Therapeutics EPS ResultsActual EPS-$0.54Consensus EPS -$0.59Beat/MissBeat by +$0.05One Year Ago EPSN/AProtagonist Therapeutics Revenue ResultsActual Revenue$4.68 millionExpected Revenue$4.50 millionBeat/MissBeat by +$180.00 thousandYoY Revenue GrowthN/AProtagonist Therapeutics Announcement DetailsQuarterDate11/7/2024TimeAfter Market ClosesConference Call ResourcesPTGX Earnings History Protagonist Therapeutics Earnings HeadlinesProtagonist Therapeutics participates in a conference call with TruistFebruary 8, 2025 | markets.businessinsider.comTruist maintains Buy on Protagonist Therapeutics with $60 targetFebruary 8, 2025 | msn.com$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out overnight as America experienced its “biggest rout in market history.” Earlier this month, China’s new AI, DeepSeek, was released to the public. Overnight it became the most-downloaded app in over 140 countries. And as it did, it sent the share prices of American AI companies tumbling.February 12, 2025 | Porter & Company (Ad)JMP Securities maintains PTGX stock with $58 targetFebruary 7, 2025 | msn.comJefferies maintains Buy on Protagonist Therapeutics, $57 targetJanuary 23, 2025 | msn.comProtagonist Therapeutics CFO Ali Asif reports stock saleJanuary 17, 2025 | msn.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX), a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead?Earnings Miss? Amgen’s Dividend Still a Bright SpotPalantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market Test Upcoming Earnings AppLovin (2/12/2025)Cisco Systems (2/12/2025)Equinix (2/12/2025)Trade Desk (2/12/2025)Sony Group (2/12/2025)Williams Companies (2/12/2025)Applied Materials (2/13/2025)Airbnb (2/13/2025)Barclays (2/13/2025)Brookfield (2/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
